A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Peter E ManleyTanya TrippettAmy A SmithMargaret E MacySarah E S LearyJessica BoklanKenneth J CohenStewart GoldmanLindsay B KilburnGirish DhallJeanne DevinCynthia E HerzogSonia PartapFloris FauchetEmmy BadreddineJohn P BernardSusan N ChiPublished in: Pediatric blood & cancer (2018)
The safety profile of cabazitaxel was consistent with previous studies. The MTD (30 mg/m2 ) was higher than the adult MTD. Cabazitaxel did not demonstrate activity in recurrent/refractory HGG or DIPG.
Keyphrases